Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CELC
stocks logo

CELC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.051
+23.66%
--
--
-1.038
+20.74%
--
--
-1.092
+4.97%
Estimates Revision
The market is revising No Change the revenue expectations for Celcuity Inc. (CELC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 90.12%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.58%
In Past 3 Month
Stock Price
Go Up
up Image
+90.12%
In Past 3 Month
Wall Street analysts forecast CELC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 98.43 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast CELC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 98.43 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 105.870
sliders
Low
70.00
Averages
98.43
High
115.00
Current: 105.870
sliders
Low
70.00
Averages
98.43
High
115.00
Wolfe Research
Outperform
initiated
$110
2025-11-17
Reason
Wolfe Research
Price Target
$110
2025-11-17
initiated
Outperform
Reason
Wolfe Research initiated coverage of Celcuity with an Outperform rating and $110 price target. Fresh off a Phase 3 win for gedatolisib in second-line PIK3CA-wt breast cancer, the firm sees additional upside as the PIK3CA-mt readout looks "primed to deliver next year," the analyst tells investors. The firm views Celcuity as "a top-tier acquisition opportunity for big pharma," the analyst added.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
$77 -> $94
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$77 -> $94
2025-11-17
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded Celcuity to Neutral from Buy with a price target of $94, up from $77. The shares look "priced for perfection," the analyst tells investors in a research note. The firm says Celcuity shares have appreciated 608% year-to-date. At current levels, there is more downside risk than upside, contends H.C. Wainwright.
Stifel
Buy
upgrade
$68 -> $115
2025-11-13
Reason
Stifel
Price Target
$68 -> $115
2025-11-13
upgrade
Buy
Reason
Stifel raised the firm's price target on Celcuity to $115 from $68 and keeps a Buy rating on the shares. Following the Q3 call and the firm's recent fireside chat with CEO Brian Sullivan, the firm is increasing its price target based on updated VIKTORIA-1 U.S. sales and odds of success estimates, the analyst tells investors.
Craig-Hallum
Chase Knickerbocker
Buy
maintain
$96 -> $108
2025-11-13
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$96 -> $108
2025-11-13
maintain
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Celcuity to $108 from $96 and keeps a Buy rating on the shares. The firm notes adjusted EPS came in at (78c) vs Street (91c). Timelines were reiterated with the NDA for PIK3CAwt on track for Q4 and early launch prep underway. The PIK3CA-mutant cohort readout is expected in Q1 2026/Q2 2026.
H.C. Wainwright
Swayampakula Ramakanth
Buy
maintain
$66 -> $77
2025-10-22
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$66 -> $77
2025-10-22
maintain
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Celcuity to $77 from $66 and keeps a Buy rating on the shares following the gedatolisib data. The firm increased the probability of launch to 90% from 80%.
Needham
Needham
Buy
maintain
$70 -> $95
2025-10-20
Reason
Needham
Needham
Price Target
$70 -> $95
2025-10-20
maintain
Buy
Reason
Needham raised the firm's price target on Celcuity (CECL) to $95 from $70 and keeps a Buy rating on the shares. The firm considers updated results from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 study as further de-risking for geda and potentially practice changing. Furthermore, Needham thinks a lack of PFS benefit observed for Roche's (RHHBY) oral SERD giredestrant in ESR1 WT patients removes an overhang on Celcuity.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Celcuity Inc (CELC.O) is -25.03, compared to its 5-year average forward P/E of -6.85. For a more detailed relative valuation and DCF analysis to assess Celcuity Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.85
Current PE
-25.03
Overvalued PE
-2.43
Undervalued PE
-11.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.28
Undervalued EV/EBITDA
-5.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
191.77
Current PS
0.00
Overvalued PS
817.78
Undervalued PS
-434.24
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CELC News & Events

Events Timeline

(ET)
2025-11-17
16:15:35
Celcuity Files New Drug Application for Gedatolisib with the FDA
select
2025-11-12 (ET)
2025-11-12
16:12:06
Celcuity Announces Q3 Adjusted EPS of 78 Cents, Below Consensus Estimate of 96 Cents
select
2025-10-20 (ET)
2025-10-20
12:01:53
Celcuity Shares Surge by 46.3%
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03NASDAQ.COM
Celcuity Shares Approach Record Levels as Prominent Biotech Investor Continues to Invest

  • Tang Capital Management's Investment: San Diego-based Tang Capital Management acquired nearly 1.2 million shares of Celcuity Inc. (CELC), valued at approximately $56.8 million, marking a new position for the fund in the third quarter.

  • Celcuity's Performance: CELC shares have surged 672% over the past year, significantly outperforming the S&P 500, which increased by 13% during the same period.

  • Company Overview: Celcuity Inc. is a clinical-stage biotechnology firm focused on developing targeted cancer therapies and companion diagnostics, with a promising pipeline led by its drug candidate Gedatolisib.

  • Market Confidence: Tang Capital's investment reflects confidence in Celcuity's clinical progress and commercialization potential, supported by recent positive Phase 3 trial results and a strong financial position with $455 million in liquidity.

[object Object]
Preview
9.0
11-27Newsfilter
Celcuity Presents Gedatolisib Data at 2025 San Antonio Breast Cancer Symposium
  • Clinical Trial Progress: Celcuity announced that its Gedatolisib study for HR+/HER2-/PIK3CA wild-type advanced breast cancer will be presented at the 2025 San Antonio Breast Cancer Symposium, showcasing updated results from the VIKTORIA-1 trial, which is expected to bolster investor confidence in its therapeutic potential.
  • Research Detail Disclosure: The presentation will include subgroup efficacy analyses and safety data, further validating Gedatolisib's effectiveness as a multi-target PI3K/AKT/mTOR inhibitor, potentially providing crucial support for the company's future clinical development.
  • Trial Status: The VIKTORIA-1 trial has completed enrollment for HR+/HER2- breast cancer patients and has reported detailed results for the PIK3CA wild-type cohort, demonstrating the company's research progress and competitive edge in this field.
  • Future Research Directions: Celcuity is also conducting the VIKTORIA-2 trial to evaluate Gedatolisib's potential as a first-line treatment, indicating the company's ongoing commitment and exploration of new therapies in breast cancer treatment.
[object Object]
Preview
8.0
11-19NASDAQ.COM
Significant Options Trading on Tuesday: CELC, FHN, VSTS

  • First Horizon Corp Options Activity: First Horizon Corp (FHN) has seen a significant options trading volume of 46,763 contracts today, equating to about 4.7 million underlying shares, which is 52.3% of its average daily trading volume.

  • High Volume Call Option for FHN: The $23 strike call option expiring on February 20, 2026, has particularly high activity with 20,173 contracts traded, representing approximately 2.0 million underlying shares.

  • Vestis Corp Options Activity: Vestis Corp (VSTS) recorded an options trading volume of 10,222 contracts today, representing around 1.0 million underlying shares, or 51.2% of its average daily trading volume.

  • High Volume Put Option for VSTS: The $5 strike put option expiring on November 21, 2025, has seen notable trading with 10,012 contracts, also representing approximately 1.0 million underlying shares.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Celcuity Inc (CELC) stock price today?

The current price of CELC is 105.87 USD — it has increased 5.87 % in the last trading day.

arrow icon

What is Celcuity Inc (CELC)'s business?

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

arrow icon

What is the price predicton of CELC Stock?

Wall Street analysts forecast CELC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 98.43 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Celcuity Inc (CELC)'s revenue for the last quarter?

Celcuity Inc revenue for the last quarter amounts to -42.85M USD, increased 42.55 % YoY.

arrow icon

What is Celcuity Inc (CELC)'s earnings per share (EPS) for the last quarter?

Celcuity Inc. EPS for the last quarter amounts to -44913000.00 USD, increased 117.89 % YoY.

arrow icon

What changes have occurred in the market's expectations for Celcuity Inc (CELC)'s fundamentals?

The market is revising No Change the revenue expectations for Celcuity Inc. (CELC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 90.12%.
arrow icon

How many employees does Celcuity Inc (CELC). have?

Celcuity Inc (CELC) has 87 emplpoyees as of December 05 2025.

arrow icon

What is Celcuity Inc (CELC) market cap?

Today CELC has the market capitalization of 4.90B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free